BD Bioscience today launched a new cloud-based system called ‘BD Synapsys Microbiology Informatics Solution’ to facilitate faster diagnostic results and improve infectious disease management.
New start-up companies are constantly commercialising new technologies and services. Genomics is ripe for investment right now.
CMO and Senior VP of Global Medical at Amgen, John Tsai, MD, is moving to Novartis to act as their new CMO and Head of Global Drug Development (GDD).
Amazon has revealed that it’s pulling out of its move to enter the pharmaceutical distribution market, despite only announcing the plans last year.
Way back when Novartis invested in personalised CAR-T cancer treatments being developed at the University of Pennsylvania, analysts pondered the tricky question: How can pharma companies profit from curing patients?
The companies plan to develop a diagnostic version of the Illumina TruSight Oncology 500 assay to measure potentially predictive biomarkers, including Tumour Mutation Burden (TMB).
The Food and Drug Administration (FDA) has, for the first time, approved an artificial intelligence diagnostic device that doesn’t need a specialised doctor to interpret the results.
If people’s explanations of what blockchain is sound like gibberish to you, there is a popular application that shares the philosophy of the blockchain technology that can help you understand how it works: Wikipedia.
French CAR-T specialist Cellectis didn’t have the best time in 2017, but it seems their luck is changing, having just closed a $164 million U.S. public offering.
GlaxoSmithKline Chief Executive, Emma Wamsley is keeping her promise to cut the drugmaker’s pharmaceutical portfolio — the company said today that it is handing its rare disease gene therapy drugs to Orchard Therapeutics.
Helix has announced two new application development deals with PerkinElmer and Northshore University Health System, in an attempt to ease access to genetic disease risk information.
Illumina and Loxo Oncology have announced a global strategic partnership to develop a diagnostic tool that will work with Loxo’s larotrectinib and another of its experimental cancers drugs, across tumour types.